The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Projected Increase In Market Value Of The Gene Therapy For Inherited Genetic Disorders Market During 2026–2030?
The gene therapy for inherited genetic disorders market has witnessed rapid growth in recent years. It is expected to expand from $4.05 billion in 2025 to $4.84 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 19.3%. Historically, this growth can be attributed to several factors including the restricted availability of advanced gene therapy techniques, the reliance on conventional treatments for genetic disorders, a rise in the prevalence of inherited genetic diseases, early clinical research focusing on viral vectors, and increasing awareness regarding rare disease management.
The gene therapy for inherited genetic disorders market size is anticipated to experience substantial growth in the coming years, with projections indicating it will reach $9.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 19.0%. This expansion during the forecast period is propelled by the ongoing development of innovative viral vectors and gene editing technologies, the broadening application of RNA-based therapies, an increasing adoption rate of ex vivo stem cell therapies, rising investments in personalized gene therapies, and the enhanced capabilities of hospitals and specialty clinics for gene therapy administration. Significant trends expected in this period include the wider application of viral vector-based therapies for rare genetic disorders, an increase in ex vivo gene therapy applications, the growing acceptance of RNA-based therapeutics, a heightened focus on treating neurological and ophthalmic disorders, and the integration of personalized medicine principles within gene therapy.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp
Which Major Drivers Are Influencing The Expansion Of The Gene Therapy For Inherited Genetic Disorders Market?
The expanding need for personalized medicine is anticipated to drive the advancement of the gene therapy for inherited genetic disorders market in the future. This approach involves customizing medical treatments based on an individual’s genetic blueprint and unique characteristics to provide optimal care. Its prevalence is on the rise, spurred by developments in genetic technologies that facilitate easier and more cost-effective customization of therapies according to a person’s distinct genetic composition. Personalized medicine significantly enhances gene therapy by adapting treatments to each patient’s specific genetic profile, thereby guaranteeing accurate gene targeting and delivery, boosting efficacy, and minimizing adverse reactions. As an illustration, in February 2024, data from the US-based non-profit Personalized Medicine Coalition indicated that the United States Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for patients with rare diseases in 2023, an increase from 6 approvals in 2022. Among the personalized treatments newly approved in 2023 were also seven medications for cancer and three for various other illnesses and conditions. Consequently, the increasing requirement for personalized medicine is fueling the expansion of the gene therapy for inherited genetic disorders market.
Which Segments Define The Gene Therapy For Inherited Genetic Disorders Market Segment Structure?
The gene therapy for inherited genetic disorders market covered in this report is segmented –
1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy
2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders
3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors
2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases
3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies
4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy
Which Trends Are Contributing To Changes In The Gene Therapy For Inherited Genetic Disorders Market?
Leading firms within the gene therapy for inherited genetic disorders market are concentrating on creating novel approaches, including ex-vivo CRISPR/Cas9-based gene-edited cell therapies. This focus aims to address the growing need for single-application, potentially curative remedies that diminish ongoing reliance on transfusions, frequent hospital stays, and substantial long-term care expenses associated with inherited blood and metabolic conditions. This ex-vivo CRISPR/Cas9 gene-edited cell therapy method entails collecting a patient’s hematopoietic stem cells, employing CRISPR/Cas9 to accurately modify genes responsible for disease (or elements that boost protective fetal hemoglobin), and subsequently reintroducing these altered cells to enable engraftment and deliver sustained therapeutic advantages. As an illustration, in December 2023, the US-based biopharmaceutical company Vertex Pharmaceuticals secured U.S. Food and Drug Administration (FDA) approval and initiated commercial release for CASGEVY (exagamglogene autotemcel). This treatment is a CRISPR/Cas9-based, ex-vivo gene-edited cell therapy designed for sickle cell disease, an inherited genetic disorder. CASGEVY is created using a patient’s own hematopoietic stem cells, which are genetically altered to elevate fetal hemoglobin. The therapy’s makeup primarily consists of autologous stem cells modified via CRISPR/Cas9. Its purpose is to achieve sustained increases in fetal hemoglobin levels, thereby preventing the sickling of red blood cells. Noteworthy attributes include accurate genome editing (CRISPR/Cas9) conducted outside the body and a single dose providing lasting results. Its chief use is for severe sickle cell disease (with other related conditions currently undergoing regulatory assessment), and trial outcomes have demonstrated significant decreases in vaso-occlusive crises and the need for transfusions when compared to previous standard treatments.
Who Are The Established Players Within The Gene Therapy For Inherited Genetic Disorders Market?
Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG
Get The Full Gene Therapy For Inherited Genetic Disorders Market Report:
Where Is The Gene Therapy For Inherited Genetic Disorders Market Most Concentrated Geographically?
North America was the largest region in the gene therapy for inherited genetic disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Gene Therapy For Inherited Genetic Disorders Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Gene Therapy For Inherited Genetic Disorders Market 2026, By The Business Research Company
Asphalt Mixing Plants Market Report 2026
https://www.thebusinessresearchcompany.com/report/asphalt-mixing-plants-global-market-report
Asphalt Pavers Market Report 2026
https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report
Asphalt Additives Market Report 2026
https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model